Fundamental Analysis of UNICYCIVE THERAPEUTICS INC(NASDAQ:UNCY) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to UNCY. UNCY was compared to 576 industry peers in the Biotechnology industry. The financial health of UNCY is average, but there are quite some concerns on its profitability. While showing a medium growth rate, UNCY is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year UNCY has reported negative net income.

UNCY had a negative operating cash flow in the past year.

UNCY had negative earnings in each of the past 5 years.

In the past 5 years UNCY always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of UNCY (-72.19%) is worse than 67.89% of its industry peers.

With a Return On Equity value of -174.03%, UNCY is not doing good in the industry: 68.94% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-72.19%
ROE	-174.03%
ROIC	N/A

ROA(3y)-305.08%

ROA(5y)-2579.05%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for UNCY so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

UNCY does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, UNCY has more shares outstanding

UNCY has more shares outstanding than it did 5 years ago.

There is no outstanding debt for UNCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -3.02, we must say that UNCY is in the distress zone and has some risk of bankruptcy.

UNCY has a Altman-Z score (-3.02) which is in line with its industry peers.

There is no outstanding debt for UNCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-3.02

ROIC/WACCN/A

WACC10.45%

2.3 Liquidity

UNCY has a Current Ratio of 1.71. This is a normal value and indicates that UNCY is financially healthy and should not expect problems in meeting its short term obligations.

UNCY's Current ratio of 1.71 is on the low side compared to the rest of the industry. UNCY is outperformed by 79.23% of its industry peers.

A Quick Ratio of 1.71 indicates that UNCY should not have too much problems paying its short term obligations.

With a Quick ratio value of 1.71, UNCY is not doing good in the industry: 78.19% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.71
Quick Ratio	1.71

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.23% over the past year.

UNCY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.

EPS 1Y (TTM)35.23%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%37.11%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 22.33% on average over the next years. This is a very strong growth

Based on estimates for the next years, UNCY will show a very strong growth in Revenue. The Revenue will grow by 233.05% on average per year.

EPS Next Y38.17%

EPS Next 2Y35.89%

EPS Next 3Y44.54%

EPS Next 5Y22.33%

Revenue Next Year-100%

Revenue Next 2Y677.06%

Revenue Next 3Y675.36%

Revenue Next 5Y233.05%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for UNCY. In the last year negative earnings were reported.

Also next year UNCY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

UNCY's earnings are expected to grow with 44.54% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y35.89%

EPS Next 3Y44.54%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for UNCY!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

UNICYCIVE THERAPEUTICS INC

NASDAQ:UNCY (7/1/2024, 7:06:31 PM)

After market: 0.54 0 (0%)

0.54

+0.04 (+7.76%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap20.31M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-72.19%
ROE	-174.03%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.71
Quick Ratio	1.71
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)35.23%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y38.17%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

UNICYCIVE THERAPEUTICS INC (UNCY)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens